Abstract: Combined radiochemotherapy treatment modalities are in use for many indications and therefore of high interest. Even though a combined modality in clinical use is often driven by prag-matic aspects, mechanistic preclinical-based concepts of interaction are of importance in order to translate and implement an optimal combination and scheduling of two modalities into the clinics. The use of microtubule stabilizing agents is a promising strategy for anti-cancer therapy as a part of combined treatment modality with ionizing radiation. Traditionally, microtubule targeting agents are classified as cytotoxic chemotherapeutics and are mostly used in a maxi-mally tolerated dose regimen. Apart from direct cytotoxicity and similar to mechanisms of mo-lecular targeting agents, microtubule stabilizing agents interfere with multiple cellular process-es, which can be exploited as part of combined treatment modalities. Recent preclinical investi-gations on the combination of ionizing radiation and microtubule stabilizing agents reveal new mechanistic interactions on the cellular and tumor level and elucidate the supra-additive tumor response observed particularly in vivo. The major focus on the mechanism of interaction was primarily based on radiosensitization due to cell cycle arrest in the most radiosensitive G2/M-phase of the cell cycle. However, other mechanisms of interaction such as reoxygenation and direct as well as indirect endothelial damage have also been identified. In this review we sum-marize and allocate additive and synergistic effects induced by the combined treatment of clini-cally relevant microtubule stabilizing agents and ionizing radiation along a described radiobio-logical framework encompassing distinct mechanisms relevant for exploiting the combination of drugs and ionizing radiation. primarily based on radiosensitization due to cell cycle arrest in the most radiosensitive G2/Mphase of the cell cycle. However, other mechanisms of interaction such as reoxygenation and direct as well as indirect endothelial damage have also been identified. In this review we summarize and allocate additive and synergistic effects induced by the combined treatment of clinically relevant microtubule stabilizing agents and ionizing radiation along a described radiobiological framework encompassing distinct mechanisms relevant for exploiting the combination of drugs and ionizing radiation.
Taxanes and epothilones are the clinically most relevant microtubule stabilizing agents. The taxanes (paclitaxel and docetaxel) have been approved for a broad range of indications, including advanced breast cancer after failure of combination chemotherapy or at early relapse,
high grade ovarian cancer in combination with platinum compounds, and primary treatment of non-small cell lung cancer in combination with cisplatin.(8) Furthermore paclitaxel is used in an "off-label manner" for other tumor types, such as cancer of unknown origin, bladder, esophagus, gastric, head and neck, and cervical cancers (reviewed in (9)). Paclitaxel has also been evaluated clinically for its radiosensitizing properties for various tumors (10) (11) (12) (13) (14) and drug plasma concentrations in patients. Low concentrations with prolonged exposure during long parts of the course of radiation therapy have been found feasible and tolerated in patients.(12-18) Docetaxel is used as first-line chemotherapy for locally advanced or metastatic breast cancer, (19) nonresectable, advanced or metastatic non-small cell lung cancer after failure of cisplatin-based therapy, hormone-refractory metastatic prostate cancer in combination with prednisone, (20) gastric adenocarcinoma in combination with cisplatin and 5-fluorouracil, (21) and inoperable Both, taxanes and epothilones, have been extensively tested at the preclinical level in combination with ionizing radiation, demonstrating a strong supra-additive treatment response. Here, we will outline classic rationales for the combined treatment modality of ionizing radiation with microtubule stabilizing agents and discuss novel mechanistic preclinical-based concepts of interaction between these two modalities.
Rationale for the Combined Use of Irradiation and Cytotoxic Agents
The rationale for a combined treatment with ionizing radiation (IR) and chemotherapy is to increase survival by improving locoregional tumor control and decrease the probability of distant A similar effect has also been described for synchronized HeLa cells, in which docetaxel resulted in a S-phase specific (and hence radioresistant) cell killing. (56, 57) Furthermore there seems to be a tendency toward a concentration-dependent increase in DNA double strand breaks after combined treatment, suggesting a reduction of DSB repair capacity as an additional mechanism of sensitization. (46) Reoxygenation theory (biological cooperation, temporal modulation). The enhanced radiation response of combined treatment with microtubule stabilizing agents and ionizing radiation has also been attributed to "tumor cell reoxygenation". Massive cell loss due to MSA-induced apop- 
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